Glutamate Receptors in Neuroinflammatory Demyelinating Disease
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis (MS) is a chronic demyelinating disease of the human central nervous system (CNS). The condition predominantly affects young adults and is characterised by immunological and inflammatory changes in the periphery and CNS that contribute to neurovascular disruption, haemopoietic cell invasion of target tissues, and demyelination of nerve fibres which culminate in neurological deficits that relapse and remit or are progressive. The main features of MS can be reproduced in the inducible animal counterpart, experimental autoimmune encephalomyelitis (EAE). The search for new MS treatments invariably employs EAE to determine drug activity and provide a rationale for exploring clinical efficacy. The preclinical development of compounds for MS has generally followed a conventional, immunotherapeutic route. However, over the past decade, a group of compounds that suppress EAE but have no apparent immunomodulatory activity have emerged. These drugs interact with the N‐methyl‐D‐aspartate (NMDA) and α‐amino‐3‐hydroxy‐5‐isoxazolepropionic acid (AMPA)/kainate family of glutamate receptors reported to control neurovascular permeability, inflammatory mediator synthesis, and resident glial cell functions including CNS myelination. The review considers the importance of the glutamate receptors in EAE and MS pathogenesis. The use of receptor antagonists to control EAE is also discussed together with the possibility of therapeutic application in demyelinating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple sclerosis: Remyelination of nascent lesions: Remyelination of nascent lesions
Prineas, J. W., Barnard, R. O., Kwon, E. E., Sharer, L. R., & Cho, E. ‐. (1993) · Annals of Neurology · doi:10.1002/ana.410330203 · Cited by 574
Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion
Rose, J. W., Hill, K. E., Watt, H. E., & Carlson, N. G. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.12.021 · Cited by 107
Cited by
Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis
Mandolesi, G., Gentile, A., Musella, A., Fresegna, D., De Vito, F., Bullitta, S., Sepman, H., Marfia, G. A., & Centonze, D. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.222 · Cited by 286
Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation
Barger, S. W., Goodwin, M. E., Porter, M. M., & Beggs, M. L. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04487.x · Cited by 254
Glutamate Receptor Expression in Multiple Sclerosis Lesions
Newcombe, J., Uddin, A., Dove, R., Patel, B., Turski, L., Nishizawa, Y., & Smith, T. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00101.x · Cited by 164
“Treatment at onset of neurological decline with AMPA/kainate receptor antagonists NBQX, MPQX, GYKI52466 and GYKI53773 resulted in marked reduction of neurological deficits in Lewis rat acute EAE independent of any effect on CNS lymphocyte infiltration, and inflammation-mediated spinal cord motor neuron degeneration wa…”
BackgroundInfluentialMechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities
Macrez, R., Stys, P. K., Vivien, D., Lipton, S. A., & Docagne, F. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30165-x · Cited by 127
Genome-wide association study of severity in multiple sclerosis
International Multiple Sclerosis Genetics Consortium, Briggs, F. B. S., Shao, X., Goldstein, B. A., Oksenberg, J. R., Barcellos, L. F., & De Jager, P. L. (2011) · Genes & Immunity · doi:10.1038/gene.2011.34 · Cited by 120
Metadata
- Authors
- Bolton, C., & Paul, C.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2006-01
- Volume
- 2006
- Issue
- 1
- Pages
- 93684-93684
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- OpenAlex
- W2075655729
- Cited by
- 78
- References
- 2
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.